110 related articles for article (PubMed ID: 30009918)
1. Biophysical and functional perturbation analyses at cancer-associated P187 and K240 sites of the multifunctional NADP(H):quinone oxidoreductase 1.
Pey AL
Int J Biol Macromol; 2018 Oct; 118(Pt B):1912-1923. PubMed ID: 30009918
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation compromises FAD binding and intracellular stability of wild-type and cancer-associated NQO1: Insights into flavo-proteome stability.
Medina-Carmona E; Rizzuti B; Martín-Escolano R; Pacheco-García JL; Mesa-Torres N; Neira JL; Guzzi R; Pey AL
Int J Biol Macromol; 2019 Mar; 125():1275-1288. PubMed ID: 30243998
[TBL] [Abstract][Full Text] [Related]
3. NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms.
Beaver SK; Mesa-Torres N; Pey AL; Timson DJ
Biochim Biophys Acta Proteins Proteom; 2019; 1867(7-8):663-676. PubMed ID: 31091472
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
5. Thermodynamics of cooperative binding of FAD to human NQO1: Implications to understanding cofactor-dependent function and stability of the flavoproteome.
Clavería-Gimeno R; Velazquez-Campoy A; Pey AL
Arch Biochem Biophys; 2017 Dec; 636():17-27. PubMed ID: 29100982
[TBL] [Abstract][Full Text] [Related]
6. Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands.
Medina-Carmona E; Palomino-Morales RJ; Fuchs JE; Padín-Gonzalez E; Mesa-Torres N; Salido E; Timson DJ; Pey AL
Sci Rep; 2016 Feb; 6():20331. PubMed ID: 26838129
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of the pleiotropic and specific phenotypic consequences of missense mutations in the multifunctional NAD(P)H:quinone oxidoreductase 1 and their pharmacological rescue.
Pacheco-Garcia JL; Anoz-Carbonell E; Vankova P; Kannan A; Palomino-Morales R; Mesa-Torres N; Salido E; Man P; Medina M; Naganathan AN; Pey AL
Redox Biol; 2021 Oct; 46():102112. PubMed ID: 34537677
[TBL] [Abstract][Full Text] [Related]
8. Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism.
Medina-Carmona E; Neira JL; Salido E; Fuchs JE; Palomino-Morales R; Timson DJ; Pey AL
Sci Rep; 2017 Mar; 7():44532. PubMed ID: 28291250
[TBL] [Abstract][Full Text] [Related]
9. A mechanism for cancer-associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80R.
Muñoz IG; Morel B; Medina-Carmona E; Pey AL
FEBS Lett; 2017 Sep; 591(18):2826-2835. PubMed ID: 28771686
[TBL] [Abstract][Full Text] [Related]
10. Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO).
Bianchet MA; Faig M; Amzel LM
Methods Enzymol; 2004; 382():144-74. PubMed ID: 15047101
[No Abstract] [Full Text] [Related]
11. Anion-specific interaction with human NQO1 inhibits flavin binding.
Pey AL
Int J Biol Macromol; 2019 Apr; 126():1223-1233. PubMed ID: 30615965
[TBL] [Abstract][Full Text] [Related]
12. Structure and mechanism of cytosolic quinone reductases.
Bianchet MA; Foster C; Faig M; Talalay P; Amzel LM
Biochem Soc Trans; 1999 Aug; 27(4):610-5. PubMed ID: 10917652
[No Abstract] [Full Text] [Related]
13. A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1.
Moscovitz O; Tsvetkov P; Hazan N; Michaelevski I; Keisar H; Ben-Nissan G; Shaul Y; Sharon M
Mol Cell; 2012 Jul; 47(1):76-86. PubMed ID: 22793692
[TBL] [Abstract][Full Text] [Related]
14. A small molecule chaperone rescues the stability and activity of a cancer-associated variant of NAD(P)H:quinone oxidoreductase 1 in vitro.
Strandback E; Lienhart WD; Hromic-Jahjefendic A; Bourgeois B; Högler A; Waltenstorfer D; Winkler A; Zangger K; Madl T; Gruber K; Macheroux P
FEBS Lett; 2020 Feb; 594(3):424-438. PubMed ID: 31605637
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of NAD(P)H:quinone reductase: Ab initio studies of reduced flavin.
Cavelier G; Amzel LM
Proteins; 2001 Jun; 43(4):420-32. PubMed ID: 11340659
[TBL] [Abstract][Full Text] [Related]
16. A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer.
Vankova P; Salido E; Timson DJ; Man P; Pey AL
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31726777
[TBL] [Abstract][Full Text] [Related]
17. Counterintuitive structural and functional effects due to naturally occurring mutations targeting the active site of the disease-associated NQO1 enzyme.
Pacheco-García JL; Anoz-Carbonell E; Loginov DS; Kavan D; Salido E; Man P; Medina M; Pey AL
FEBS J; 2023 Apr; 290(7):1855-1873. PubMed ID: 36378023
[TBL] [Abstract][Full Text] [Related]
18. A two-domain structure for the two subunits of NAD(P)H:quinone acceptor oxidoreductase.
Chen S; Deng PS; Bailey JM; Swiderek KM
Protein Sci; 1994 Jan; 3(1):51-7. PubMed ID: 7511454
[TBL] [Abstract][Full Text] [Related]
19. Different phenotypic outcome due to site-specific phosphorylation in the cancer-associated NQO1 enzyme studied by phosphomimetic mutations.
Pacheco-Garcia JL; Anoz-Carbonell E; Loginov DS; Vankova P; Salido E; Man P; Medina M; Palomino-Morales R; Pey AL
Arch Biochem Biophys; 2022 Oct; 729():109392. PubMed ID: 36096178
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NAD(P)H:quinone acceptor oxidoreductase by flavones: a structure-activity study.
Chen S; Hwang J; Deng PS
Arch Biochem Biophys; 1993 Apr; 302(1):72-7. PubMed ID: 8470908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
